[{"orgOrder":0,"company":"Uni-Pharma SA","sponsor":"Attikon Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"GREECE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"Thyroid hormone receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Uni-Pharma SA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Uni-Pharma SA \/ Attikon Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Uni-Pharma SA \/ Attikon Hospital"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"THR","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"M. Medici","sponsor":"ZonMw | ACE Pharmaceuticals BV","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Liothyronine Sodium","moa":"Thyroid hormone receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"M. Medici","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M. Medici \/ ZonMw | ACE Pharmaceuticals BV","highestDevelopmentStatusID":"10","companyTruncated":"M. Medici \/ ZonMw | ACE Pharmaceuticals BV"}]

Find Clinical Drug Pipeline Developments & Deals for Triiodothyronine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          M. Medici

                          Country arrow
                          EPSC
                          Not Confirmed

                          M. Medici

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 12, 2023

                          Lead Product(s) : Liothyronine Sodium

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : ZonMw | ACE Pharmaceuticals BV

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Liothyronine is a man-made form of thyroid hormone which is used to treat an underactive thyroid (hypothyroidism). Zydus Cadila has received final approval from the USFDA to market Liothyronine Sodium Tablets USP, 5 mcg, 25 mcg, and 50 mcg (US RLD: Cytom...

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          January 23, 2021

                          Lead Product(s) : Liothyronine Sodium

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 16, 2020

                          Lead Product(s) : Liothyronine Sodium

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Attikon Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Musli Thyropeutics Ltd

                          Country arrow
                          EPSC
                          Not Confirmed

                          Musli Thyropeutics Ltd

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 13, 2016

                          Lead Product(s) : Liothyronine Sodium

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Tel Aviv Sourasky Medical Center (Ichilov Hospital)

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          National Cardiovascular Center Harapan Kita Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          National Cardiovascular Center Harapan Kita Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 13, 2015

                          Lead Product(s) : Liothyronine Sodium

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase III

                          Sponsor : CRDF Global | Osypka Medical | Dalim BioTech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Ipe, LLC

                          Country arrow
                          EPSC
                          Not Confirmed

                          Ipe, LLC

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          February 27, 2013

                          Lead Product(s) : Liothyronine Sodium

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Ipe, LLC

                          Country arrow
                          EPSC
                          Not Confirmed

                          Ipe, LLC

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          April 20, 2012

                          Lead Product(s) : Liothyronine Sodium

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank